4311/B Ciba en es it fr

4311/B Ciba Brand names, 4311/B Ciba Analogs

4311/B Ciba Brand Names Mixture

  • No information avaliable

4311/B Ciba Chemical_Formula


4311/B Ciba RX_link


4311/B Ciba fda sheet

4311/B_Ciba FDA

4311/B Ciba msds (material safety sheet)

4311/B_Ciba MSDS

4311/B Ciba Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

4311/B Ciba Molecular Weight

233.306 g/mol

4311/B Ciba Melting Point


4311/B Ciba H2O Solubility


4311/B Ciba State


4311/B Ciba LogP


4311/B Ciba Dosage Forms

Tablets; Tablets (sustained release)

4311/B Ciba Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

4311/B Ciba Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

4311/B Ciba Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

4311/B Ciba side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

4311/B Ciba Patient Information

4311/B Ciba Organisms Affected

Humans and other mammals